Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
Completed · Phase 1
Conditions studied: Leukemia
In brief
RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
Key facts
- Study ID
- NCT00030303
- Run by
- UConn Health
- People needed
- 20
- Starts
- 2001-01-01
- Expected to finish
- 2004-01-01
- Last updated by the study team
- 2017-04-28
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Connecticut Health Center — Farmington, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.